ALLEGAN, Mich. -- Perrigo received the green light from the Food and Drug Administration to manufacture and market private label OTC tioconazole ointment and migraine-strength pain relievers.
Perrigo's tioconazole ointment is the equivalent to Bristol-Myers Squibb's Vagistat-1 vaginal yeast infection treatment, and the migraine remedy is likewise the store brand version of BMS' Excedrin Migraine.
Perrigo pegged one-dose treatments as one of the fastest-growing segments in the feminine hygiene category, with retail sales approaching $60 million over the past 12 months. For its part, Excedrin Migraine pulled in $53.9 million in all channels excepting Wal-Mart) during calendar 2001--almost one-third of that through the drug channel, according to Information Resources data.
Commenting on the approvals, Mark Olesnavage, executive vice president at Perrigo, commented, "These new products are expected to begin shipping by our fourth quarter [which ends] June 29, 2002. Also, with our migraine formula, we will receive 180 days of generic drug exclusivity following initial shipments."
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group